In particular EGFR inhibitors for EGFR-mutant NSCLC and the mutation-selective RAF and MEK inhibitors for BRAF-mutant melanoma [10] are examples of successfully targeted therapy selection. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.